{
"info": {
"nct_id": "NCT05884801",
"official_title": "A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of QLS1103 in Subjects With Advanced Solid Tumors",
"inclusion_criteria": "* 1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;\n* 2. Aged ≥18 years old;\n* 3. Histologically or cytologically confirmed advanced or recurrent or metastatic solid tumor;\n* 4. Failure of adequate standard treatment, or no effective standard treatment;\n* 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1;\n* 6. Life expectancy ≥12 weeks;\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "* 1. Subjects received systemic anticancer therapy within 4 weeks prior to the first dose;\n* 2. Subjects received experimental medication or therapy within 4 weeks prior to the first dose;\n* 3. Subjects received major surgery within 4 weeks prior to the first dose;\n* 4. Persistent toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade >1 severity that is related to prior therapy;\n* 5. Cardiovascular and cerebrovascular diseases with clinical significance;\n* 6. Active gastrointestinal disease or other conditions that significantly interfere with drug absorption.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* 1. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form;",
"criterions": [
{
"exact_snippets": "Subjects must voluntarily agree to participate in the trial",
"criterion": "voluntary agreement to participate",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "sign a written informed consent form",
"criterion": "informed consent form",
"requirements": [
{
"requirement_type": "signed",
"expected_value": true
}
]
}
]
},
{
"line": "* 2. Aged ≥18 years old;",
"criterions": [
{
"exact_snippets": "Aged ≥18 years old",
"criterion": "age",
"requirements": [
{
"requirement_type": "value",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* 3. Histologically or cytologically confirmed advanced or recurrent or metastatic solid tumor;",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed",
"criterion": "tumor confirmation method",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
},
{
"exact_snippets": "advanced or recurrent or metastatic solid tumor",
"criterion": "tumor stage",
"requirements": [
{
"requirement_type": "stage",
"expected_value": [
"advanced",
"recurrent",
"metastatic"
]
}
]
}
]
},
{
"line": "* 4. Failure of adequate standard treatment, or no effective standard treatment;",
"criterions": [
{
"exact_snippets": "Failure of adequate standard treatment",
"criterion": "standard treatment",
"requirements": [
{
"requirement_type": "effectiveness",
"expected_value": false
}
]
},
{
"exact_snippets": "no effective standard treatment",
"criterion": "standard treatment",
"requirements": [
{
"requirement_type": "availability",
"expected_value": false
}
]
}
]
},
{
"line": "* 5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1;",
"criterions": [
{
"exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1",
"criterion": "ECOG performance status",
"requirements": [
{
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
]
}
]
},
{
"line": "* 6. Life expectancy ≥12 weeks;",
"criterions": [
{
"exact_snippets": "Life expectancy ≥12 weeks;",
"criterion": "life expectancy",
"requirements": [
{
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 12,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* 1. Subjects received systemic anticancer therapy within 4 weeks prior to the first dose;",
"criterions": [
{
"exact_snippets": "Subjects received systemic anticancer therapy within 4 weeks prior to the first dose",
"criterion": "systemic anticancer therapy",
"requirements": [
{
"requirement_type": "time since last treatment",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 2. Subjects received experimental medication or therapy within 4 weeks prior to the first dose;",
"criterions": [
{
"exact_snippets": "Subjects received experimental medication or therapy within 4 weeks prior to the first dose",
"criterion": "experimental medication or therapy",
"requirements": [
{
"requirement_type": "time since last administration",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 3. Subjects received major surgery within 4 weeks prior to the first dose;",
"criterions": [
{
"exact_snippets": "Subjects received major surgery within 4 weeks prior to the first dose",
"criterion": "major surgery",
"requirements": [
{
"requirement_type": "time since surgery",
"expected_value": {
"operator": "<=",
"value": 4,
"unit": "weeks"
}
}
]
}
]
},
{
"line": "* 5. Cardiovascular and cerebrovascular diseases with clinical significance;",
"criterions": [
{
"exact_snippets": "Cardiovascular and cerebrovascular diseases with clinical significance",
"criterion": "cardiovascular diseases",
"requirements": [
{
"requirement_type": "clinical significance",
"expected_value": true
}
]
},
{
"exact_snippets": "Cardiovascular and cerebrovascular diseases with clinical significance",
"criterion": "cerebrovascular diseases",
"requirements": [
{
"requirement_type": "clinical significance",
"expected_value": true
}
]
}
]
},
{
"line": "* 6. Active gastrointestinal disease or other conditions that significantly interfere with drug absorption.",
"criterions": [
{
"exact_snippets": "Active gastrointestinal disease",
"criterion": "gastrointestinal disease",
"requirements": [
{
"requirement_type": "activity",
"expected_value": true
}
]
},
{
"exact_snippets": "other conditions that significantly interfere with drug absorption",
"criterion": "conditions interfering with drug absorption",
"requirements": [
{
"requirement_type": "interference",
"expected_value": "significant"
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [
{
"line": "* 4. Persistent toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Grade >1 severity that is related to prior therapy;",
"criterions": [
{
"exact_snippets": "Persistent toxicity ... NCI CTCAE Grade >1 severity ... related to prior therapy",
"criterion": "persistent toxicity",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": ">",
"value": 1,
"unit": "NCI CTCAE Grade"
}
},
{
"requirement_type": "relation to prior therapy",
"expected_value": true
}
]
}
]
}
],
"failed_miscellaneous": []
}